Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
0 |
-0.74 |
N/A |
N/A |
2024-04-01 |
2023-12 |
0 |
-0.63 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.62 |
-0.82 |
-0.2 |
-32.26% |
2023-08-09 |
2023-06 |
-0.6 |
-0.7 |
-0.1 |
-16.67% |
2023-05-09 |
2023-03 |
-0.55 |
-0.63 |
-0.08 |
-14.55% |
2023-03-13 |
2022-12 |
0 |
-0.73 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-12-07 |
UBS |
Downgrade |
Buy |
Neutral |
2022-11-07 |
B of A Securities |
Downgrade |
Neutral |
Underperform |
2022-06-07 |
B of A Securities |
Downgrade |
Buy |
Neutral |
2021-10-18 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2021-10-07 |
JP Morgan |
Downgrade |
Neutral |
Underweight |
2021-10-05 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2013-10-23 |
ASPIRI RAY |
Director |
227.18K |
Conversion of Exercise of derivative security |
2023-09-11 |
BUMOL THOMAS F. PH.D. |
Director |
0.00 |
Stock Award(Grant) |
2023-05-21 |
CABLE THOMAS J |
Director |
35.07K |
Sale |
2023-11-16 |
DEMOPULOS GREGORY A. M.D. |
Chief Executive Officer |
0.00 |
Purchase |
2023-11-14 |
DEMOPULOS PETER A |
Director |
372.90K |
Purchase |
2023-05-21 |
HANISH ARNOLD C |
Director |
12.40K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Ingalls & Snyder |
4.66M |
25.33M |
7.41% |
2023-06-29 |
Blackrock Inc. |
4.15M |
22.60M |
6.61% |
2023-06-29 |
Vanguard Group Inc |
3.14M |
17.07M |
4.99% |
2023-06-29 |
Stifel Financial Corporation |
2.06M |
11.19M |
3.27% |
2023-06-29 |
Shaw D.E. & Co., Inc. |
1.64M |
8.92M |
2.61% |
2023-06-29 |
Geode Capital Management, LLC |
1.25M |
6.82M |
1.99% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.82M |
9.91M |
2.90% |
2023-08-30 |
iShares Russell 2000 ETF |
1.35M |
4.68M |
2.15% |
2023-06-29 |
Vanguard Extended Market Index Fund |
895.03K |
4.87M |
1.42% |
2023-07-30 |
Fidelity Small Cap Index Fund |
534.59K |
2.33M |
0.85% |
2023-05-30 |
Fidelity Extended Market Index Fund |
326.20K |
2.02M |
0.52% |
2023-08-30 |
iShares Russell 2000 Value ETF |
313.05K |
1.08M |
0.50% |